MENU
HAE
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

HAE stock forecast, quote, news & analysis

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces... Show more

A.I.Advisor
published price charts
HAE
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for HAE with price predictions
Oct 05, 2026

HAE's Stochastic Oscillator sits in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +0.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where HAE advanced for three days, in 235 of 341 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

The Aroon Indicator entered an Uptrend today. In 153 of 201 cases where HAE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.

Bearish Trend Analysis

The 10-day RSI Indicator for HAE moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 28 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.

The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HAE as a result. In 42 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

The Moving Average Convergence Divergence Histogram (MACD) for HAE turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 24 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HAE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

HAE broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. HAE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.750) is normal, around the industry mean (10.853). P/E Ratio (51.106) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (1.676) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.668) is also within normal values, averaging (39.828).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 5.55B. The market cap for tickers in the group ranges from 837 to 174.73B. ABT holds the highest valuation in this group at 174.73B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was 8%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 4%. PACB experienced the highest price growth at 68%, while CVRX experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was 99% and the average quarterly volume growth was 36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 74
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 95
Seasonality Score: 10 (-100 ... +100)
HAE's Stochastic Oscillator sits in oversold zone for 3 days